Ibrutinib and Hair texture abnormal - a phase IV clinical study of FDA data

Summary:

Hair texture abnormal is reported only by a few people who take Ibrutinib.

The phase IV clinical study analyzes which people take Ibrutinib and have Hair texture abnormal. It is created by eHealthMe based on reports of 10,952 people who have side effects while taking Ibrutinib from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 28, 2023

10,952 people reported to have side effects when taking Ibrutinib.
Among them, 3 people (0.03%) have Hair texture abnormal.

What is Ibrutinib?

Ibrutinib has active ingredients of ibrutinib. eHealthMe is studying from 10,958 Ibrutinib users for its effectiveness, alternative drugs and more.

What is Hair texture abnormal?

Hair texture abnormal is found to be associated with 1,227 drugs and 648 conditions by eHealthMe.

Number of Ibrutinib and Hair texture abnormal reports submitted per year:

Could Ibrutinib cause Hair texture abnormal?

Gender of people who have Hair texture abnormal when taking Ibrutinib *:

female: 33.33 %
male: 66.67 %

Age of people who have Hair texture abnormal when taking Ibrutinib *:

Common drugs people take besides Ibrutinib *:

Revlimid: 2 people, 66.67%
Latuda: 1 person, 33.33%

Common side effects people have besides Hair texture abnormal *:

Trismus (reduced opening of the jaws): 2 people, 66.67%
Tooth Disorder (tooth disease): 2 people, 66.67%
Prostatic Specific Antigen Increased: 2 people, 66.67%
Prostate Cancer: 2 people, 66.67%
Onychoclasis (breaking of the nails): 2 people, 66.67%
Muscle Spasms (muscle contraction): 2 people, 66.67%
Haemorrhage (bleeding): 2 people, 66.67%
Diarrhea: 2 people, 66.67%
Tremor (trembling or shaking movements in one or more parts of your body): 1 person, 33.33%
Stress And Anxiety: 1 person, 33.33%

Common conditions people have *:

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 66.67%
Affective Disorder (mental disorder): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrutinib and have Hair texture abnormal?

Check whether Hair texture abnormal is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Hair texture abnormal and when was it recovered:

Hair texture abnormal in Ibrutinib

Expand to all the drugs that have ingredients of ibrutinib:

Hair texture abnormal and drugs with ingredients of ibrutinib

Alternative drugs to, pros and cons of Ibrutinib:

Ibrutinib (10,958 reports)

Common Ibrutinib side effects:

Browse all side effects of Ibrutinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hair texture abnormal treatments and more:

Hair texture abnormal (17,471 reports)

COVID vaccines that are related to Hair texture abnormal:

Common drugs associated with Hair texture abnormal:

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Ibrutinib) and Ibrutinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.